zoledronic acid

FDA Drug Profile — zoledronic acid, Reclast, Zoledronic Acid, Zoledronic acid

Drug Details

Generic Name
zoledronic acid
Brand Names
zoledronic acid, Reclast, Zoledronic Acid, Zoledronic acid
Application Number
ANDA202828
Sponsor
Sagent Pharmaceuticals
NDC Codes
14
Dosage Forms
INJECTION, SOLUTION, INJECTION, SOLUTION, CONCENTRATE, INJECTION, POWDER
Routes
INTRAVENOUS
Active Ingredients
ZOLEDRONIC ACID, ZOLEDRONIC ACID ANHYDROUS

Indications and Usage

1 INDICATIONS AND USAGE Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2) Limitations of Use : The safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. 1.1 Hypercalcemia of Malignancy Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL=Ca in mg/dL + 0.8 ( 4.0 g/dL - patient albumin [g/dL]). 1.2 Multiple Myeloma and Bone Metastases of Solid Tumors Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non–tumor-related conditions have not been established.